Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.